News

Araris, Novago and Tolremo are nominated for Strüngmann Award

Au, Schlieren, and Basel, Switzerland — A Swiss company will receive the Strüngmann Award for revolutionary technologies in the life science sector in the DACH region in 2025. The nominees are Araris in Au, NovaGo in Schlieren, and Tolremo in Basel. Three companies from Switzerland have been nominated for the Strüngmann...

read more

Positive Phase 2 trial interim analysis on safety and efficacy for denovoSkin™ in pediatric burn patients

CUTISS has completed an interim analysis in its Phase 2 clinical trial evaluating the safety and efficacy of denovoSkin™ in children with severe burns, with positive results. The randomized, controlled trial enrolled 12 pediatric patients, comparing denovoSkin™ to the current standard of care (autografting) using an intra-patient control design. The results from...

read more

GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases

Newton, MA & Wädenswil, Switzerland – May 27, 2025– GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, today announced the closing of an oversubscribed $130 million Series B financing. The proceeds will be used to advance the Company’s lead IgG4-targeted protein degrader...

read more

SISCAPA and Biognosys Announce Strategic Collaboration to Deliver End-to-End High-Sensitivity Targeted Protein Quantification Solutions

WASHINGTON, D.C. and ZUERICH, Switzerland – May 19, 2025 – (GlobeNewswire) – SISCAPA Assay Technologies, a global leader in high-sensitivity protein quantitation, and Biognosys, a pioneer in next-generation proteomics, today announced an exclusive strategic collaboration to offer biopharma customers a streamlined end-to-end solution for high-sensitivity protein analysis—from early protein biomarker and drug target discovery, all...

read more

Molecular Partners Reports Financial Results and Highlights from Q1 2025

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...

read more